Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Lymphangioleiomyomatosis × Letrozole × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 196 Polycystic Ovary Syndrome 32 Endometrial Neoplasms 14 Ovarian Neoplasms 13 Neoplasm Metastasis 9 Infertility 8 Fallopian Tube Neoplasms 6 Carcinoma, Intraductal, Noninfiltrating 6 Osteoporosis 4 Neoplasms 4 Leiomyoma 4 Infertility, Female 4 Breast Neoplasms, Male 4 Breast Diseases 4 Arthralgia 4 Advanced Breast Cancer 4 Triple Negative Breast Neoplasms 3 Recurrence 3 Obesity 3 Breast Carcinoma In Situ 3 Breast Cancer Metastatic 3 Uterine Neoplasms 2 Solid Tumor 2 Prostatic Neoplasms 2 Progesterone Resistance 2 Pancreatic Neoplasms 2 Pain 2 Leiomyosarcoma 2 Estrogen Receptor-positive Breast Cancer 2 Endometrial Hyperplasia 2

Interventions

Sirolimus 9 Imatinib Mesylate 2 Everolimus 2 temsirolimus 1 saracatinib 1 carbon-11 acetate 1 Valproic Acid 1 Urination 1 Sugars 1 Simvastatin 1 Resveratrol 1 Respiratory Function Tests 1 Phlebotomy 1 Loratadine 1 Letrozole 1 Immunoglobulin G 1 Hydroxychloroquine 1 Genetic Testing 1 Doxycycline 1 Disulfides 1 Cetuximab 1 Celecoxib 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01353209 2024-04-17

TRAIL

University of Cincinnati

Phase 2 Completed

17 enrolled 13 charts

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡